{"id":"eptifibatide-integrilin","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Bleeding"},{"rate":"1-2","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"2-5","effect":"Bradycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eptifibatide reversibly binds to the glycoprotein IIb/IIIa receptor on platelet surfaces, inhibiting the final common pathway of platelet aggregation. By blocking fibrinogen and von Willebrand factor from cross-linking platelets, it prevents thrombus formation. This mechanism reduces ischemic complications in patients undergoing percutaneous coronary intervention or those with acute coronary syndromes.","oneSentence":"Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:26.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)"},{"name":"Percutaneous coronary intervention"}]},"trialDetails":[{"nctId":"NCT07347626","phase":"PHASE3","title":"Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis","status":"NOT_YET_RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2026-03-01","conditions":"Acute Ischemic Stroke","enrollment":786},{"nctId":"NCT03735979","phase":"PHASE3","title":"Multi-arm Optimization of Stroke Thrombolysis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-10-15","conditions":"Acute Ischemic Stroke","enrollment":514},{"nctId":"NCT00089895","phase":"PHASE3","title":"EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11-01","conditions":"Myocardial Ischemia, Acute Coronary Syndrome","enrollment":9406},{"nctId":"NCT05415150","phase":"PHASE1, PHASE2","title":"Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic","status":"UNKNOWN","sponsor":"Baylor College of Medicine","startDate":"2022-02-18","conditions":"Acute Ischemic Stroke","enrollment":30},{"nctId":"NCT01991366","phase":"","title":"Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?","status":"WITHDRAWN","sponsor":"Medstar Health Research Institute","startDate":"2013-10","conditions":"ST-elevation Myocardial Infarction, Acute Myocardial Infarction","enrollment":""},{"nctId":"NCT01522417","phase":"PHASE2","title":"Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Medicure","startDate":"2012-04","conditions":"Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina","enrollment":535},{"nctId":"NCT02925923","phase":"PHASE2","title":"Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2016-11-01","conditions":"Acute Coronary Syndrome, Angina, Unstable","enrollment":100},{"nctId":"NCT03844594","phase":"PHASE3","title":"Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)","status":"UNKNOWN","sponsor":"Ministry of Science and Technology of the People´s Republic of China","startDate":"2019-04-06","conditions":"Acute Ischemic Stroke","enrollment":220},{"nctId":"NCT01103440","phase":"PHASE2","title":"Aspirin Resistance and Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-04","conditions":"Stable Angina","enrollment":36},{"nctId":"NCT03383393","phase":"","title":"Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG","status":"UNKNOWN","sponsor":"Alexandrovska University Hospital","startDate":"2018-01-03","conditions":"Coronary Ischemia","enrollment":60},{"nctId":"NCT02204852","phase":"PHASE2","title":"Co-administration of Iloprost and Eptifibatide in Septic Shock Patients","status":"COMPLETED","sponsor":"Sisse R. Ostrowski, MD PhD DMSc","startDate":"2014-09","conditions":"Septic Shock","enrollment":18},{"nctId":"NCT01919723","phase":"PHASE2","title":"Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-02","conditions":"Acute Coronary Syndrome","enrollment":70},{"nctId":"NCT01076764","phase":"PHASE3","title":"Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-04","conditions":"Acute Coronary Syndrome","enrollment":13220},{"nctId":"NCT01532544","phase":"PHASE2","title":"Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis","status":"TERMINATED","sponsor":"Thrombologic ApS","startDate":"2012-06","conditions":"Pneumonia","enrollment":5},{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":"Acute Coronary Syndrome","enrollment":2198},{"nctId":"NCT01977456","phase":"PHASE2","title":"Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)","status":"COMPLETED","sponsor":"Arthur Pancioli","startDate":"2013-09","conditions":"Stroke, Brain Infarction","enrollment":27},{"nctId":"NCT01994941","phase":"PHASE4","title":"Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2013-08","conditions":"Acute Coronary Syndrome","enrollment":133},{"nctId":"NCT01433627","phase":"PHASE3","title":"Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX","status":"UNKNOWN","sponsor":"Italian Society of Invasive Cardiology","startDate":"2011-10","conditions":"Acute Coronary Syndromes, STEMI, NSTEMI","enrollment":7200},{"nctId":"NCT00317395","phase":"PHASE2","title":"Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Coronary Disease","enrollment":3241},{"nctId":"NCT00812435","phase":"PHASE3","title":"Eptifibatide and ST Segment Resolution Following Primary PCI","status":"TERMINATED","sponsor":"Medstar Health Research Institute","startDate":"2007-08","conditions":"Myocardial Infarction","enrollment":22},{"nctId":"NCT00894803","phase":"PHASE2","title":"Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2009-07","conditions":"Ischemic Stroke, Stroke, Brain Infarction","enrollment":126},{"nctId":"NCT00111566","phase":"PHASE4","title":"BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Cardiology Research UBC","startDate":"2004-12","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":624},{"nctId":"NCT01863134","phase":"PHASE4","title":"Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2005-01","conditions":"Non ST Elevation Myocardial Infarction","enrollment":140},{"nctId":"NCT00834899","phase":"PHASE1, PHASE2","title":"A Safety Study of Eptifibatide in Patients With Sickle Cell Disease","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-01","conditions":"Sickle Cell Disease","enrollment":13},{"nctId":"NCT00061373","phase":"PHASE2","title":"Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-05","conditions":"Ischemic Stroke","enrollment":18},{"nctId":"NCT00426751","phase":"PHASE3","title":"Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Infarction, Myocardial","enrollment":429},{"nctId":"NCT00719914","phase":"PHASE2","title":"A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2007-11","conditions":"ST-Elevation Myocardial Infarction","enrollment":31},{"nctId":"NCT01454440","phase":"PHASE4","title":"The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)","status":"TERMINATED","sponsor":"University of Turin, Italy","startDate":"2007-10","conditions":"Coronary Artery Disease","enrollment":91},{"nctId":"NCT00638976","phase":"PHASE3","title":"INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial","status":"COMPLETED","sponsor":"Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS","startDate":"2007-11","conditions":"Cardiovascular Disease","enrollment":91},{"nctId":"NCT00945308","phase":"PHASE2","title":"Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2009-08","conditions":"Acute Myocardial Infarction","enrollment":50},{"nctId":"NCT00250991","phase":"PHASE1, PHASE2","title":"Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2003-07","conditions":"Stroke","enrollment":94},{"nctId":"NCT00251823","phase":"PHASE3","title":"Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2005-07","conditions":"Myocardial Infarction","enrollment":400},{"nctId":"NCT00289601","phase":"PHASE4","title":"Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2006-03","conditions":"Angioplasty","enrollment":1200},{"nctId":"NCT00370045","phase":"PHASE4","title":"Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin","status":"UNKNOWN","sponsor":"LifeBridge Health","startDate":"2006-03","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT00250471","phase":"PHASE3","title":"PROTECT-TIMI 30 Trial","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2003-05","conditions":"Unstable Angina","enrollment":900}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"POST PROCEDURAL COMPLICATION"},{"count":2,"reaction":"POST PROCEDURAL PAIN"},{"count":1,"reaction":"BLOOD CREATINE PHOSPHOKINASE MB INCREASED"},{"count":1,"reaction":"BLOODY DISCHARGE"},{"count":1,"reaction":"ECCHYMOSIS"},{"count":1,"reaction":"ENZYME ABNORMALITY"},{"count":1,"reaction":"GROIN PAIN"},{"count":1,"reaction":"POST PROCEDURAL HAEMATOMA"}],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Integrilin","SCH 060936","SCH 60936"],"phase":"phase_3","status":"active","brandName":"Eptifibatide (Integrilin)","genericName":"Eptifibatide (Integrilin)","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors. Used for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), Percutaneous coronary intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}